title: The relationship among microsomal enzyme induction, liver weight, and histological change in cynomolgus monkey toxicology studies.
abstract: The purpose of this investigation was to examine the relationship among hepatic microsomal enzyme induction, liver weight, histological evidence of hepatic injury, and serum clinical chemistry markers of hepatic origin in the cynomolgus monkey. We report here the results from independent toxicology studies for 10 investigative drug candidates representing four therapeutic classes. Study conditions were selected to elicit target organ toxicity. We found that six of the 10 compounds altered cytochrome P450-associated activities in both male and female monkeys, two in females only, and one altered similar activities in males only. Frequently, significant treatment-related elevations in NADPH cytochrome c reductase and ethylmorphine N-demethylase were noted. When the results from all 10 studies were pooled, 14 cytochrome P450-associated activities were significantly increased and five were decreased in males compared to 15 significantly increased and three decreased in the females. Treatment-associated liver weight increases were noted in four studies. Except for hepatocellular hypertrophy in one study, no significant treatment-related microscopic changes in liver and no elevations of serum biomarkers commonly associated with liver toxicity were observed in any of the studies that demonstrated significant hepatic enzyme induction. Compared to parallel rat studies, one compound was an inducer only in monkeys and one was an inducer only in rats. Significant elevations of microsomal drug-metabolizing enzymes in the cynomolgus monkey liver are not accompanied by substantial hepatic changes except for hepatomegaly. These alterations in the hepatic drug-metabolizing enzyme system were benign based the absence of histopathological lesions and serum biomarkers of hepatobiliary toxicity.
authors.affiliation: World-wide Safety Sciences, Pfizer Global Research and Development, Groton, CT 06340, USA. david.e.amacher@pfizer.com
authors.forename: David E
authors.initials: DE
authors.lastname: Amacher
authors.forename: Shelli J
authors.initials: SJ
authors.lastname: Schomaker
authors.forename: Sherri E
authors.initials: SE
authors.lastname: Boldt
authors.forename: Michael
authors.initials: M
authors.lastname: Mirsky
mesh_terms: D000818:Animals; D003577:Cytochrome P-450 Enzyme System / Q000096:biosynthesis* / Q000187:drug effects; D004790:Enzyme Induction; D005260:Female; D000882:Haplorhini; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008297:Male; D008862:Microsomes, Liver / Q000187:drug effects* / Q000201:enzymology*; D019055:No-Observed-Adverse-Effect Level; D051381:Rats; D013045:Species Specificity; D018675:Toxicity Tests
chemical_list: D003577:Cytochrome P-450 Enzyme System